Table 3 Demographic characteristics for adults populations studied, stratified by observation period
At-risk adults aged 19–64 years | High-Risk Adults Age 19–64 Years | Immunocompetent adults aged 65+ | Immunocompromised Adults Age 65+ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug 2013 – Jul 2014 (Baseline Period) N = 16,193 | May 2015 – Apr 2016 (Interim Period) N = 18,423 | May 2016 – Jul 2017 (Follow-up Period) N = 21,498 | Aug 2013 – Jul 2014 (Baseline Period) N = 2658 | May 2015 – Apr 2016 (Interim Period) N = 3449 | May 2016 – Jul 2017 (Follow-up period) N = 3612 | Aug 2013 – Jul 2014 (Baseline Period) N = 9480 | May 2015 – Apr 2016 (Interim Period) N = 11,318 | May 2016 – Jul 2017 (Follow-up Period) N = 13,341 | Aug 2013 – Jul 2014 (Baseline Period) N = 2577 | May 2015 – Apr 2016 (Interim Period) N = 3200 | May 2016 – Jul 2017 (Follow-up Period) N = 3348 | |
Age | ||||||||||||
Median age | 45 | 45 | 45 | 53 | 53 | 53 | 72 | 71 | 71 | 74 | 74 | 73 |
Mean age (SD) | 44.13 (12.70) | 44.06 (12.73) | 43.87 (12.79) | 50.28 (10.99) | 50.15 (11.08) | 49.75 (11.26) | 73.49 (7.19) | 73.19 (7.06) | 73.13 (7.02) | 75.11 (7.61) | 74.81 (7.30) | 74.60 (7.21) |
Sex n (%) | ||||||||||||
Male | 7327 (45.25) | 8290 (45.00) | 9733 (45.27) | 1111 (41.80) | 1411 (40.91) | 1402 (38.82) | 3698 (39.01) | 4555 (40.25) | 5353 (40.12) | 1308 (50.76) | 1596 (49.88) | 1654 (49.40) |
Female | 8866 (54.75) | 10,133 (55.00) | 11,765 (54.73) | 1547 (58.20) | 2038 (59.09) | 2210 (61.18) | 5782 (60.99) | 6763 (59.75) | 7988 (59.88) | 1269 (49.24) | 1604 (50.13) | 1694 (50.60) |